Advancing a short-course, G6PD test-independent therapy designed to eliminate dormant liver-stage malaria and prevent relapse
April 24, 2026
Malaria affects over 250 million people every year. Yet one of the most stubborn barriers to eradication — relapse driven by dormant liver-stage parasites — remains chronically under-addressed.
Today, on #WorldMalariaDay, AliquantumRx reaffirms our commitment to changing that.
We’re developing Cethromycin HCl, a short-course therapy designed to eliminate liver-stage malaria without requiring G6PD testing — removing a major implementation barrier in low-resource settings.
Our approach is built on three pillars: Liver-stage targeting — addressing the root cause of relapse, not just the symptoms Short-course, exposure-bounded treatment — designed for real-world compliance Clear path to proof-of-concept — leveraging existing cethromycin base safety data to move fast.
We’re on track for IND submission in 2026, with Phase I and liver-stage challenge studies to follow.
This week, we joined global health leaders at the Johns Hopkins Bloomberg School of Public Health symposium to discuss what it will take to make malaria elimination a reality.
As our Chairman and Johns Hopkins Malaria Research Institute professor David Sullivan put it: “Progress against malaria is not guaranteed. Focused innovation will determine whether elimination remains achievable.”
We couldn’t agree more. The science is ready. The urgency is real.
About AliquantumRx Inc.
AliquantumRx is a near-clinical infectious-disease company developing Cethromycin HCl, a glucose-6-phosphate dehydrogenase (G6PD) test-independent, short-course therapy designed to eliminate dormant liver-stage malaria and prevent relapse.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, the matters set forth above may be forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially, including regulatory outcomes and clinical development timelines. AliquantumRx undertakes no obligation to update such statements.
#Malaria #GlobalHealth #InfectiousDisease #DrugDevelopment #WorldMalariaDay2026 #AliquantumRx